Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04907305 · ClinicalTrials.gov registry record
Next-Gen MS: Feed-forward PRO Data for MS Research
A clinical trial, sponsored by EMD Serono Research & Development Institute.
- Terminated
- Registry status
- 1,594
- Enrollment target
NCT04907305: Clinical Trial study, sponsored by EMD Serono Research & Development Institute.
NCT04907305 is a clinical trial that was terminated before completion, run by EMD Serono Research & Development Institute. The registered enrollment target is 1,594 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04907305 was terminated before completion, sponsored by EMD Serono Research & Development Institute.
- TERMINATED
- Registry status
- 1,594 participants
- Enrollment target
Study Summary
This Next Generation learning health system for Multiple Sclerosis (Next-Gen MS) study is a sub-study of the MS-LINK™ Outcomes Study (NCT04735406). The study aims to examine the effects of using feed forward Patient Reported Outcomes (PROs) data in real-world Multiple Sclerosis (MS) care settings. The study will be conducted within an emerging Learning Healthcare System (LHS).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,594 participants |
| Start Date | 2021-11-02 |
| Est. Completion | 2024-02-19 |
Why NCT04907305 stopped before completion
NCT04907305 is an observational study that tracks outcomes without assigning an intervention. Its 1,594 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT04907305 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04907305 about?
NCT04907305 is a clinical study titled "Next-Gen MS: Feed-forward PRO Data for MS Research". This Next Generation learning health system for Multiple Sclerosis (Next-Gen MS) study is a sub-study of the MS-LINK™ Outcomes Study (NCT04735406). The study aims to examine the effects of using feed forward Patient Reported Outcomes (PROs) data in real-world Multiple Sclerosis (MS) care settings. T...
What is the current status of trial NCT04907305?
This trial is currently terminated. The enrollment target is 1,594 participants. The study started on 2021-11-02. Estimated completion is 2024-02-19.
Who is sponsoring clinical trial NCT04907305?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05243797 · 1,594 participants · Phase 3
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- NCT05552222 · 1,590 participants · Phase 3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- NCT06632457 · 1,590 participants · Phase 3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- NCT00646022 · 1,600 participants
Natural History of Familial Carcinoid Tumor
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI